Ada Patient Finder -- Daily Briefing

Pipeline Snapshot

€96,833,305

Total Pipeline (Unweighted)

€7,907,039

Weighted Pipeline

133

Open Opps

€0

Closing This Quarter

7

Calls Yesterday

3.1

7-Day Avg Calls

69

Stale Deals

Stage Moves (Last 24h)

Boehringer Ingelheim Jascayd Patient Finder Advanced

Moved from Qualification | 5% to Discovery | 10% (Karen VanOverberghe)
€421,059

Pipeline Changes

BMS - Patient finder Camzyos Removed

Eran Desheh | Discovery | 10%

Stale Deals (14+ Days Since Last Contact)

Crohns Colitis Foundation 378d No Contact

Jacob Plummer | Qualification | 5% | €421,060

Ontario Enhancements - Suicide Pop Up - Delivery 267d No Contact

Simon Wolpert | Qualification | 5% | €248,122

Ontario SOW9 - Health Care Connect (Primary Care Attachment) - Planning Only 208d No Contact

Simon Wolpert | Proposal | 30% | €31,015

Astrazeneca - Wainua 161d No Contact

Usaid Cheema | Qualification | 5% | €500,000

Walgreens/Boots 157d No Contact

Randal Whitmore | Qualification | 5% | €421,060

Patient Finder for Temple Health 156d No Contact

Randal Whitmore | Qualification | 5% | €421,060

Health 811 SOW9 - HCC + Survey Planning + Delivery 149d No Contact

Simon Wolpert | Proposal | 30% | €93,046

DKV Seguros 143d No Contact

Johannes Vonhuelsen | Discovery | 10% | €486,000

GSK - Shingrix 127d No Contact

Usaid Cheema | Qualification | 5% | €421,060

Alberta Health Services - Patient Portal (via Orion & Telus/IBM) 96d No Contact

Simon Wolpert | Qualification | 5% | €4,807,378

+59 more stale deals

No Decision Maker Engaged

AbbVie - Botox No DM

Usaid Cheema | Qualification | 5% | €421,060

AbbVie - Rinvoq No DM

Usaid Cheema | Qualification | 5% | €421,060

AbbVie - Vraylar No DM

Usaid Cheema | Qualification | 5% | €500,000

ACADIA Pharmaceuticals | Daybue | Rett syndrome No DM

Usaid Cheema | Qualification | 5% | €421,060

Acorda Therapeutics | Ampyra | Multiple sclerosis (improve walking) No DM

Usaid Cheema | Qualification | 5% | €421,060

Aetna a CVS Health Company No DM

Simon Wolpert | Qualification | 5% | €252,636

Alberta Health Services - Patient Portal (via Orion & Telus/IBM) No DM

Simon Wolpert | Qualification | 5% | €4,807,378

Alkermes - Libalvi No DM

Usaid Cheema | Qualification | 5% | €500,000

+20 more

Flagged Calls (< 3.0)

No flagged calls

Calls Yesterday (7)

DigiPharma Connect Kick-off 30m

Participants:

US marketing consent journey walk through 8m

Participants:

Jefferson Specialty Referrals Internal Sync 28m

Participants:

Pipeline Review - Eran & team (Weekly) 29m

Participants:

Jacob / Karen 40m

Participants:

SDM <> Ada Weekly Connect 24m

Participants:

PurpleLab + Ada 61m

Participants:

Top Deals by Value

GNAL
Qualification | 5%

€20,500,000

Biogen | Friedreichs Ataxia | Global - Phase 2
Qualification | 5%

€6,000,000

Blue Shield of California
Proposal | 30%

€5,473,780

Alberta Health Services - Patient Portal (via Orion & Telus/IBM)
Qualification | 5%

€4,807,378

Resmed Phase 2
Qualification | 5%

€2,526,360

SANOFI | Diabetes | TZIELD | US - Phase 2
Discovery | 10%

€2,526,360

Biogen Germany FA extension
Discovery | 10%

€2,100,000

Blue Cross Blue Shield Arizona
Qualification | 5%

€1,431,604

Pharma Intel -- Urgent

### Sanofi CEO Change: Paul Hudson OUT, Belen Garijo IN

- **Sanofi's Board decided Feb 11 not to renew Paul Hudson's contract.** His last day is Feb 17, 2026. Interim CEO: Olivier Charmeil (EVP General Medicines). Belen Garijo (current Merck KGaA CEO, former Sanofi exec for 15 years) takes over April 29 a

- Reason: R&D setbacks, pipeline concerns as Dupixent patent approaches early 2030s expiry.

- **Patient Finder impact: HIGH.** Daniel has a warm direct relationship with Paul Hudson. This relationship resets. Garijo is a known quantity (ex-Sanofi, ran Genzyme integration) but outreach strategy must pivot immediately. Interim period (Feb 17

- Sources: [Sanofi PR](https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-12-06-30-00-3236866), [STAT](https://www.statnews.com/2026/02/12/sanofi-ceo-replaced-paul-hudson-belen-garijo/), [FiercePharma](https://www.fiercepharma.com/pharm

### Novartis Acquires Avidity Biosciences for ~$12B

- Deal for RNA therapeutics (AOC platform) targeting neuromuscular diseases (DMD, DM1, FSHD). Closing H1 2026. Spin-off record date: Feb 12.

- **Patient Finder impact: MEDIUM.** Novartis deepening in rare neuromuscular = potential Patient Finder use case for undiagnosed DMD/DM1 patients. Flag for Andrea Marazzi conversation. Rare disease patient finding is squarely in our wheelhouse.

Meetings Today

8:00 AM

Prof. Arenas

10:30 AM

Prof. Nissanoff

2:00 PM

Health Evolution Roundtable Discussion on Achieving Consumer-Centric Care Experiences

2:00 PM

Strategy Block

3:00 PM -- Katrin Pucknat

Katrin/Daniel connect

5:00 PM

Sophia Piano Lesson

System Health

Cron Jobs0 active

Stale Tasks6